Doxercalciferol
It is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1a, 25-dihydroxyvitamin D,a naturally occurring, biologically active form the vitamin D2.Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
4mg administered intravenously as a bolus dose three times weekly at the end of dialysis (approximately every other day). The initial dose should be adjusted, as needed, in order to lower blood iPTH into the range of 150 to 300pg/mL.
Patient suffering from hypercalcemia, during Vitamin D toxicity.
During the early phase of treatment (i.e., first 12 weeks), serum iPTH, calcium, and phosphorus levels should be determined weekly. Pregnancy : Use with caution and if indicated (Category B). Lactation : It is not known whether doxercalciferol is excreated in human milk.
Weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste, and other signs & symptoms of hypercalcemia or hyperphosphetemia.
Cytochrome P450 inducer or inhibitor may alter the metabolism so dose adjustment is needed. Magnesium containing antacid should be avoided to prevent hypermagnesemia.
